Complement Blockade, a New Therapeutic Approach in Malignant Hypertension

1 Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390: 681–96. Search in Google Scholar

2 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyo JM, Macia M, Mendizabal S, Praga M, Roman E, Torra R, Valdes F, Vilalta R, Rodriguez de Cordoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35:421–47. Search in Google Scholar

3 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654. Atypical Hemolytic Uremic Syndrome, Last updated: February 10, 2020 Search in Google Scholar

4 rarediseases.org/rare-diseases/atypical-hemolyticuremic-syndrome/ Search in Google Scholar

5 Puraswani M, Khandelwal P, Saini H, et al. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019; 10:1282. Search in Google Scholar

6 Sinha A, Gulati A, Saini S, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014; 85:1151. Search in Google Scholar

7 Menne, J., Delmas, Y., Fakhouri, F. et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC N ephrol 20, 125 (2019). https://doi.org/10.1186/s12882-019-1314-1 As cited by Wijnsma KL et Al. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Search in Google Scholar

8 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39. doi: 10.1007/s00467-015-3076-8 Search in Google Scholar

9 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ, Conference P. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91:539–551. doi: 10.1016/j.kint.2016.10.005. Search in Google Scholar

10 Food and drug administration (2011) Approval Package for Soliris Search in Google Scholar

11 European Medicines Agency (2017) Summary of product characteristics Search in Google Scholar

12 Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M (2017) Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 10.1007/s00467-017-3813-2 Search in Google Scholar

13 Gatault P, Brachet G, Ternant D, Degenne D, Recipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs. 2015;7:1205–1211. doi: 10.1080/19420862.2015.1086049. Search in Google Scholar

14 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Erratum in: Pediatr Nephrol. 2019 Jan 15;: PMID: 30402748; PMCID: PMC6794245 Search in Google Scholar

15 Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Bruggemann RJ, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102: 671–678. doi: 10.1002/cpt.686. Search in Google Scholar

16 Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clin Immunol. 2017;183:1–7. doi: 10.1016/j.clim.2017.06.007. Search in Google Scholar

17 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tonshoff B, Buscher R, Fehrenbach H, Gok ON, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187:304–315. doi: 10.1111/cei.12890. Search in Google Scholar

18 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715–1726. doi: 10.1182/blood-2014-02-558296. Search in Google Scholar

19 www.uptodate.com Search in Google Scholar

20 Macia M, et al: Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 2017; 10: 310–319. Search in Google Scholar

21 akhouri F, et al: Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 2017; 12: 50–59. Search in Google Scholar

22 Cugno M, et al: Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440–1448. Search in Google Scholar

23 Sven R. Olson, Eric Lu, Emilio Sulpizio, Joseph J. Shatzel, Jose F. Rueda, Thomas G. DeLoughery; When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol 22 August 2018; 48 (2): 96–107. Search in Google Scholar

24 Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434–46. https://doi.org/10.1016/j.ekir.2018.11.010. Search in Google Scholar

25 Timothy H.J. Goodship1, H. Terence Cook2, Fadi Fakhouri3, Fernando C. Fervenza4, Véronique Frémeaux-Bacchi5, David Kavanagh1, Carla M. Nester6,7, Marina Noris8, Matthew C. Pickering2, Santiago Rodrírdoba9, Lubka T. guez de Có Roumenina10,11,12, Sanjeev Sethi13 and Richard J.H. Smith: Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes Kidney International (2017) 91, 539–551; http://dx.doi.org/10.1016/j.kint.2016.10.005 Search in Google Scholar

26 Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. CJASN. 2010;5(10). https://doi.org/10.2215/CJN.02210310. Search in Google Scholar

27 Kant, S., Bhalla, A., Alasfar, S. et al. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome–a single center experience. BMC Nephrol 21, 189 (2020). https://doi.org/10.1186/s12882-020-01847-0 Search in Google Scholar